Page 50 - ESGO - Vulvar cancer - Complete report_fxd2

MMC mitomycin C PET positron emission tomography
MRI magnetic resonance imaging PET-CT positron emission tomography-computed
MSAC medical services advisory committee tomography
MTX methotrexate PFS progression-free survival
NA not available PR partial response
NCCN national comprehensive cancer network Recurr recurrence
NED no evidece of disease and no recurrence RCT randomised controlled trial
NHMRC national health and medical research SIGN Scottish intercollegiate guidelines network
council SLN sentinel lymph node
NHS national health service Tax paclitaxel
NICE national institute for health and care TN true negative
excellence TP true positive
NZGG New Zealand guidelines group UICC union internationale contre le cancer
OR odd ratio VinC vincristine
ORR overall response rate
OS overall survival
pCR pathologic complete response

 VULVAR CANCER - GUIDELINES 
50